DEXA Scan Reliability in CKD Stage 3b
Evidence Supporting DEXA Reliability in CKD 3b
- The American Journal of Kidney Diseases and Annals of Internal Medicine suggest that DEXA scanning is a reliable tool for assessing bone mineral density and predicting fracture risk in patients with CKD stage 3b, and should be employed when results will impact treatment decisions, particularly in those with fractures or osteoporosis risk factors 1, 2
- DEXA bone mineral density testing predicts fractures in CKD stage 3a to 5D patients with comparable accuracy to the general population, according to Annals of Internal Medicine and Kidney International 2, 3
- Prospective cohort studies demonstrate that hip BMD consistently predicts fractures across the spectrum from CKD stage 3a to 5D, with associations similar to those seen in patients without CKD, as reported in Annals of Internal Medicine 2
Updated Guideline Recommendations
- The Kidney Disease: Improving Global Outcomes (KDIGO) guideline update suggests BMD testing in CKD G3a to G5D patients with evidence of CKD-MBD and/or osteoporosis risk factors if results will impact treatment decisions, with a Grade 2B recommendation 2
- The World Health Organization T-scores predict fracture risk similarly in patients with and without CKD, including in kidney transplant recipients, according to Kidney International 3
Specific Clinical Applications in CKD 3b
- DEXA should be employed in CKD patients with fractures or known risk factors for osteoporosis, including menopause, gonadal hormone deficiency, smoking, Caucasian race, age >65 years, and glucocorticoid use, as recommended by the American Journal of Kidney Diseases 1, 4
- Patients receiving glucocorticoid therapy for >3 months should undergo DEXA scanning, according to the American Journal of Kidney Diseases 1, 6
Important Limitations and Caveats
- DEXA cannot distinguish among different types of renal osteodystrophy, and bone biopsy remains the gold standard for determining bone turnover type when this information is needed to guide therapy, as reported in Annals of Internal Medicine and Kidney International 2, 3
- DEXA measures bone quantity but not bone quality, turnover, or mineralization status, according to Kidney International 3
Comparison with Alternative Methods
- DEXA may overestimate BMD in CKD patients compared to quantitative CT, but remains the recommended first-line imaging modality due to lower radiation exposure, wider availability, and established fracture prediction data, as reported in Annals of Internal Medicine and Kidney International 2, 3, 9
- Bone biopsy is the gold standard for diagnosing renal osteodystrophy type, but is no longer a prerequisite for initiating osteoporosis therapy in CKD stage 3-4 patients, according to Annals of Internal Medicine 2